West Nile Virus (WNV) Comprehensive Antibody Testing

West Nile Virus (WNV) is a mosquito-borne pathogen belonging to the Flavivirus genus. While many infections remain asymptomatic, WNV is a critical focus in neurovirology due to its potential to cause severe neuroinvasive diseases, including West Nile encephalitis and meningitis, particularly in vulnerable or immunocompromised subjects.

In biomedical research, infectious disease modeling, and epidemiological surveillance, tracking the serological response to WNV is essential. However, flavivirus immunology presents unique challenges due to extensive cross-reactivity among related viruses. A highly structured, targeted testing approach is required to accurately decipher the host's immune timeline and isolate specific WNV exposure from other flavivirus background signals.

Our Services

We offer high-precision Enzyme Immunoassay (EIA) platforms tailored for the comprehensive serological profiling of WNV. Our testing panel captures the two primary immunoglobulins to map the complete kinetic timeline of the host's immune response:

• WNV IgM Antibody Assay: IgM is the frontline indicator of acute exposure. In typical models, WNV IgM antibodies appear rapidly, usually within 3 to 8 days post-onset of symptoms. These antibodies typically persist for 30 to 90 days, though in some specific long-term cohorts, they have been documented to last for up to 500 days.
• WNV IgG Antibody Assay: IgG antibodies emerge shortly after the initial IgM response, signifying the transition to long-term immune memory. Once established, WNV IgG persists for over 500 days, providing critical baseline data for past exposure and long-term immunity evaluations.

Assay Limitations & Cross-Reactivity Protocol

Due to the structural similarities within the Flavivirus genus, serological cross-reactivity is extremely common. Antibodies generated against viruses such as Dengue, Japanese Encephalitis (JEV), St. Louis Encephalitis (SLEV), and Yellow Fever can produce false-positive signals in WNV EIA tests.

To maintain strict scientific rigor, we integrate the following protocols:

1. Targeted Application: The performance of this assay has not been established for general population screening. Testing should be strictly targeted at research models or cohort subjects exhibiting specific clinical symptoms consistent with WNV encephalitis.
2. Neutralization Confirmation: For any positive or equivocal EIA results in cross-endemic research regions, we strongly recommend and provide subsequent neutralizing antibody testing (e.g., Plaque Reduction Neutralization Test, PRNT) to definitively confirm WNV specificity.

Sample Requirements

To ensure optimal optical signaling in the EIA platform and prevent matrix interference, please strictly adhere to our sample guidelines:

• Preferred Specimen: Serum.
• Preferred Volume: 1.0 mL is highly recommended to allow for initial screening and necessary neutralization confirmation testing.
• Minimum Volume: 0.5 mL.
• Rejection Criteria: To guarantee data integrity, our laboratory will categorically reject specimens exhibiting any of the following conditions:
  • Severe contamination
  • Severe hemolysis (destruction of red blood cells)
  • Icteric serum (high bilirubin/jaundice)
  • Lipemic specimens (high lipid content)